Clinical-stage biotechnology company developing targeted therapies for autoimmune diseases
Clinical-stage biotechnology company developing targeted therapies for autoimmune diseases. Its lead program, telitacicept (TACI-Fc), is a dual BAFF/APRIL inhibitor designed to reduce harmful B-cell activity and autoantibody production, with potential applications across conditions including myasthenia gravis, Sjögren’s disease, lupus, rheumatoid arthritis, and IgA nephropathy.